Molecular Characteristics and Survival Rates in the Patients with Gastrointestinal Stromal Tumors: A Retrospective Single-Center Study
- 1Research Institute of Experimental Oncology and Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, Kashirskoye Sh. 24, 115478 Moscow, Russia
- 2Research Institute of Clinical Oncology, N.N. Blokhin National Medical Research Center of Oncology, Kashirskoye Sh. 24, 115478 Moscow, Russia
- 3A.S. Loginov Moscow Clinical Scientific and Practical Center, Enthusiasts Sh. 86, 111123 Moscow, Russia
Abstract
Background/Objectives: Gastrointestinal stromal tumors (GISTs) are the most common malignant mesenchymal tumors that compose a heterogeneous group due to various molecular alterations. This study aimed to determine the molecular characteristics of patients with GIST treated between 2002 and 2017 and to follow their overall survival (OS) over 20 years. Methods: DNA was isolated from surgical biopsies of 490 patients with gut sarcomas and was analyzed using PCR and Sanger sequencing of hotspots of KIT, PDGFRA and BRAF genes. Immunohistochemical (IHC) staining was used to determine SDHB expression. Results: 417 GIST patients, including 13 children, were included; females predominated (male-to-female ratio 0.65), median age of 55.4 years old. KIT and PDGFRA mutations were found in 288 GISTs (69.1%) and 52 (12.5%), respectively. A total of 25 KIT and 3 novel PDGFRA mutations were revealed in 30 GISTs. KIT/PDGFRA mutations were not detected in 77 (18.5%) GISTs; among them were 2 NF1 GISTs, 10 with BRAF mutation, 14 with SDHB deficiency, and 3 “pediatric” GISTs. The overall survival (OS) of 280 GIST patients over more than 20 years. Genetic changes have a certain prognostic value in addition to such factors as tumor size, mitotic index, and location. The OS of GIST patients with KIT mutations was lower than that of patients with PDGFRA mutation, BRAF mutation, or SDHB deficiency, but the difference was non-significant. Conclusions: Our study highlights the heterogeneous nature and molecular features of GISTs in Russian population. The precise molecular characterization of the tumor should be considered an integral part of modern personalized GIST treatment.
Related
- Diffuse brainstem gliomas across the pediatric, adolescent, and adult age spectrum: Clinical and radiological features, molecular profile, and determinants of survival in a multicenter retrospective cohort of 42 patients.
- Dissociation Between Symptom Burden and Structural Pathology in Patients Undergoing Upper Gastrointestinal Endoscopy: A Retrospective Single-Center Study Using Latent Class Analysis
- Trends and disparities in upper gastrointestinal cancer among patients with metabolic comorbidities: a retrospective CDC-WONDER analysis (1999–2020)
- Tranexamic acid use and progression to clinically important bleeding in critically ill patients with non-clinically important non-variceal upper gastrointestinal bleeding: a retrospective cohort study
- Association Between Overweight and Obesity and the Occurrence of Small Intestinal Bacterial Overgrowth (SIBO) in Children and Adolescents Referred for Gastrointestinal Symptoms: A Cross-Sectional Study with Analysis of Patients’ Demographic Characteristics
BibTeX
@article{mazurenko2026molecular,
title = {{Molecular Characteristics and Survival Rates in the Patients with Gastrointestinal Stromal Tumors: A Retrospective Single-Center Study}},
author = {Natalia N. Mazurenko and Irina V. Tsyganova and Vladimir V. Yugay and Olga A. Anurova and Ilya S. Beliakov and Anna A. Lushnikova and Maxim P. Nikulin and Nikolay A. Kozlov and Petr P. Arhiri and Daria A. Filonenko and Ivan S. Stilidi},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18203298},
url = {https://www.mdpi.com/2072-6694/18/20/3298},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Molecular Characteristics and Survival Rates in the Patients with Gastrointestinal Stromal Tumors: A Retrospective Single-Center Study
AU - Natalia N. Mazurenko
AU - Irina V. Tsyganova
AU - Vladimir V. Yugay
AU - Olga A. Anurova
AU - Ilya S. Beliakov
AU - Anna A. Lushnikova
AU - Maxim P. Nikulin
AU - Nikolay A. Kozlov
AU - Petr P. Arhiri
AU - Daria A. Filonenko
AU - Ivan S. Stilidi
PY - 2026
DA - 2026/10/01
JO - Cancers
DO - 10.3390/cancers18203298
UR - https://www.mdpi.com/2072-6694/18/20/3298
AB - Background/Objectives: Gastrointestinal stromal tumors (GISTs) are the most common malignant mesenchymal tumors that compose a heterogeneous group due to various molecular alterations. This study aimed to determine the molecular characteristics of patients with GIST treated between 2002 and 2017 and to follow their overall survival (OS) over 20 years. Methods: DNA was isolated from surgical biopsies of 490 patients with gut sarcomas and was analyzed using PCR and Sanger sequencing of hotspots of KIT, PDGFRA and BRAF genes. Immunohistochemical (IHC) staining was used to determine SDHB expression. Results: 417 GIST patients, including 13 children, were included; females predominated (male-to-female ratio 0.65), median age of 55.4 years old. KIT and PDGFRA mutations were found in 288 GISTs (69.1%) and 52 (12.5%), respectively. A total of 25 KIT and 3 novel PDGFRA mutations were revealed in 30 GISTs. KIT/PDGFRA mutations were not detected in 77 (18.5%) GISTs; among them were 2 NF1 GISTs, 10 with BRAF mutation, 14 with SDHB deficiency, and 3 “pediatric” GISTs. The overall survival (OS) of 280 GIST patients over more than 20 years. Genetic changes have a certain prognostic value in addition to such factors as tumor size, mitotic index, and location. The OS of GIST patients with KIT mutations was lower than that of patients with PDGFRA mutation, BRAF mutation, or SDHB deficiency, but the difference was non-significant. Conclusions: Our study highlights the heterogeneous nature and molecular features of GISTs in Russian population. The precise molecular characterization of the tumor should be considered an integral part of modern personalized GIST treatment.
SN - 2072-6694
ER -